10 November 2017Americas

LSIPR 50 2017: Steve Bossone

Name: Steve Bossone

Organisation: Alnylam Pharmaceuticals

Position: Vice president, IP

Steve Bossone works as vice president, IP at Alnylam Pharmaceuticals. He joined the company in 2010, having spent 15 years at biopharmaceutical company Shire.

At Shire, he worked as a senior patent attorney and provided licensing, acquisition and litigation support in the management of several marketed products.

Bossone began his career at Millennium Pharmaceuticals after it was gradually absorbed by parent company Takeda. While at Millennium, he worked as head of the transcript profiling group, which supported drug discovery initiatives.

He has also worked in senior positions at biopharmaceutical company ToleRx and biotech business Soledo.

In 2013, Bossone featured in a report by the World Intellectual Property Organization (WIPO) and BIO Ventures for Global Health (BVGH) called “2013 Partnership Hub Report: Catalysing Partnerships for Global Health”.

The report was released in cooperation with WIPO’s sponsors, which included Alnylam, GSK, Novartis, Pfizer and AstraZeneca.

“The partnership between WIPO, BVGH, and our members represents a new paradigm for consortium management,” the report said.

"By participating in WIPO Re:Search, Alnylam expects to augment its efforts in the area of global health."

The report explained that the BVGH continued to reach out to its members to learn about their research programmes, areas of expertise, capabilities and partnering interests.

“As a biopharmaceutical company, Alnylam recognises the large impact a smaller industry player can have in the neglected disease field. By participating in WIPO Re:Search, Alnylam expects to augment its efforts in the area of global health, while also demonstrating the utility and impact our technology can have worldwide,” Bossone said in the report.